Results 1 to 10 of about 9,061 (176)

Prediction of severe neutropenia and diarrhoea in breast cancer patients treated with abemaciclib

Breast, 2021
Introduction: Neutropenia and diarrhoea are common and potentially serious adverse events associated with abemaciclib in advanced breast cancer (ABC), and the risk factors have been minimally explored. The study aimed to develop clinical prediction tools
Ashley M. Hopkins, Ross A. McKinnon, Ahmad Y Abuhelwa   +2 more
exaly   +4 more sources

Gilteritinib Enhances Anti-Tumor Efficacy of CDK4/6 Inhibitor, Abemaciclib in Lung Cancer Cells

Frontiers in Pharmacology, 2022
Abemaciclib is a cyclin-dependent kinases 4/6 (CDK4/6) inhibitor approved for the treatment of metastatic breast cancer. Preclinical studies suggest that abemaciclib has the potential for lung cancer treatment.
Milton Talukder, Cun-Wu Chen, Chao-Yue Sun   +2 more
exaly   +3 more sources

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

Cell Reports, 2018
Summary: Abemaciclib, an inhibitor of cyclin dependent kinases 4 and 6 (CDK4/6), has recently been approved for the treatment of hormone receptor-positive breast cancer.
Kirk Alan Staschke, Michael Kalos, Sean G Buchanan   +2 more
exaly   +3 more sources

Inhibition of CDK4/6 regulates AD pathology, neuroinflammation and cognitive function through DYRK1A/STAT3 signaling

Pharmacological Research, 2023
Repurposing approved drugs is an emerging therapeutic development strategy for Alzheimer's disease (AD). The CDK4/6 inhibitor abemaciclib mesylate is an FDA-approved drug for breast cancer treatment.
Hyun-ju Lee, Hyang-Sook Hoe
doaj   +1 more source

Pharmacokinetic study on the co-administration of abemaciclib and astragaloside IV in rats

Pharmaceutical Biology, 2022
Context The co-administration of abemaciclib and astragaloside IV might occur in the treatment of breast cancer.Objective This study evaluates the interaction between abemaciclib and astragaloside IV in rats and describes the potential mechanism ...
Sen Sun, Lu Liu, Hongming Song, Hong Li
doaj   +1 more source

Abemaciclib does not increase the corrected QT interval in healthy participants

Clinical and Translational Science, 2023
Abemaciclib is an orally administered, potent, and selective small molecule inhibitor of cyclin‐dependent kinases 4 and 6, approved for advanced or metastatic breast cancer.
Jill C. Chappell, Alan Y. Chiang, Jane Royalty, Hugh Coleman, Palaniappan Kulanthaivel, P. Kellie Turner   +5 more
doaj   +1 more source

Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trial

Cancer Medicine, 2023
Background Pancreatic ductal adenocarcinomas (PDAC) are characterized by frequent cell cycle pathways aberrations. This study evaluated safety and efficacy of abemaciclib, a cyclin‐dependent kinase 4 and 6 inhibitor, as monotherapy or in combination with
E. Gabriela Chiorean, Vincent Picozzi, Chung‐Pin Li, Marc Peeters, Joan Maurel, Jaswinder Singh, Talia Golan, Jean‐Frédéric Blanc, Sonya C. Chapman, Anwar M. Hussain, Erica L. Johnston, Howard S. Hochster   +11 more
doaj   +1 more source

A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER

Frontiers in Oncology, 2020
IntroductionJUNIPER compared the efficacy and safety of abemaciclib, a selective cyclin-dependent kinase 4 and 6 inhibitor, with erlotinib in patients with non-small cell lung cancer (NSCLC) harboring a Kirsten rat sarcoma (KRAS) mutation.MethodsJUNIPER ...
Jonathan W. Goldman, Julien Mazieres, Fabrice Barlesi, Konstantin H. Dragnev, Marianna Koczywas, Tuncay Göskel, Alexis B. Cortot, Nicolas Girard, Claas Wesseler, Helge Bischoff, Ernest Nadal, Keunchil Park, Shun Lu, Alvaro Taus, Manuel Cobo, Shawn T. Estrem, Sameera R. Wijayawardana, Kellie Turner, Gerard Joseph Oakley, Karla C. Hurt, Alan Y. Chiang, Anwar M. Hossain, William J. John, Luis Paz-Ares   +23 more
doaj   +1 more source

Abemaciclib [PDF]

Reactions Weekly, 2021
  +6 more sources

Hormone receptor-positive, HER2-negative, metastatic breast cancer responded well to abemaciclib and exemestane after palbociclib and fulvestrant failure: A case report and literature review

Frontiers in Oncology, 2023
There is uncertainty regarding the usefulness of CDK4/6-inhibitor-based therapy for hormone receptor positive (HR+), human epidermal grow factor receptor 2 negative (HER2−), metastatic breast cancer (MBC), when CDK4/6 inhibitor treatment had previously ...
Yan Mao, Meng Lv, Yongmei Wang, Weihong Cao, Wenfeng Li   +4 more
doaj   +1 more source